Moderna CEO Expects Low EU COVID Sales In 2025 And 2026 As Pfizer Contract Ends In 2026
Portfolio Pulse from Benzinga Newsdesk
Moderna's CEO anticipates lower COVID-19 vaccine sales in the EU for 2025 and 2026 due to the expiration of Pfizer's contract in 2026.
August 01, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Moderna's CEO expects a decline in COVID-19 vaccine sales in the EU for 2025 and 2026, which could impact the company's revenue projections.
The anticipated decline in vaccine sales in the EU for 2025 and 2026 could negatively impact Moderna's revenue, leading to a potential decrease in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Pfizer's contract for COVID-19 vaccines in the EU is set to end in 2026, which may lead to a decrease in sales and revenue for the company.
The expiration of Pfizer's COVID-19 vaccine contract in the EU in 2026 could result in reduced sales and revenue, potentially affecting the stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80